FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to gynaecology, and can be used for the prediction of recurrent carcinoma of the vulva. To this effect, treatment is preceded by examining the patient's blood for large granular lymphocytes (LGLs) and circulating immune complexes (CICs). If the LGL level is more than 11.8%, and the CIC level is less than 33.3 standard units, a recurrence-free period for 5 years and more is predicted. If the LGL level is less than 9.8% and the CIC level is more than 42.7 standard units, a recurrence progression for the following 2 years is predicted.
EFFECT: using the given method enables conducting the most effective therapeutic measures in the patients with unfavourable prognosis, as well as indicates a necessity of the regular careful case follow-up accompanied by the additive clinical-laboratory examinations.
4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTION OF RECURRENT VULVAR CANCER I AND II STAGE | 2015 |
|
RU2608508C1 |
METHOD FOR REMISSION DURATION PREDICTION IN PATIENTS WITH VULVA CANCER | 2016 |
|
RU2624508C1 |
METHOD FOR PREDICTING COURSE OF TUMOUR PROCESS IN PATIENTS WITH VULVAR CANCER | 2015 |
|
RU2613119C1 |
METHOD FOR ONCOLOGICAL DISEASES COURSE PREDICTION | 2016 |
|
RU2622756C1 |
METHOD FOR PREDICTION OF RECURRENT VULVAR CANCER | 2013 |
|
RU2517541C1 |
METHOD FOR PREDICTING THE DURATION OF RELAPSE-FREE PERIOD IN PATIENTS WITH MAMMARY CANCER | 2003 |
|
RU2251692C2 |
METHOD FOR PREDICTION OF CERVICAL CANCER METASTASES | 2010 |
|
RU2436102C1 |
METHOD FOR MALIGNANT TUMOUR DISEASE RECURRENCE PREDICTION | 2015 |
|
RU2620306C2 |
METHOD FOR PREDICTING VULVA CANCER TREATMENT RESULTS | 1998 |
|
RU2153175C1 |
METHOD OF DETERMINING EFFICIENCY OF TREATMENT OF UTERINE BODY CANCER | 2010 |
|
RU2424806C1 |
Authors
Dates
2014-11-10—Published
2013-08-20—Filed